AbbVie Inc AbbVie (NYSE: ABBV) Announces FDA Extended Review Period for Upadacitinib’s NDA AbbVie Inc. (NYSE: ABBV) declared that FDA has made the decision regarding the supplemental New Drug Application (sNDA) for upadacitinib. FDA has decided that it will extend the review period for sNDA for upadacitinib.
Bristol-Myers Squibb Company (BMY) FDA Approves Bristol Myers (NYSE: BMY) Mavacamten NDA for Review Bristol-Myers Squibb Company (NYSE: BMY) disclosed Friday that FDA has acknowledged the New Drug Application (NDA) of Mavacamten. FDA has decided to review the NDA of Mavacamten which is an investigational drug for the cure of the cardiac condition.
Takeda Pharmaceutical Company Limited Takeda (NYSE: TAK) Announces Submission Of NDA For Lanadelumab In Japan Takeda Pharmaceutical Company Limited (NYSE: TAK) declared Friday that it has submitted New Drug Application (NDA) for Lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan.